BG
MLAB icon

Bahl & Gaynor’s Mesa Laboratories MLAB Stock Holding History

Bahl & Gaynor’s Portfolio MLAB Stock Details MLAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-8,986
Closed -$986K – 340
2024
Q1 		$986K Sell
8,986
-2
-0% -$201 0.01% 249
2023
Q4 		$942K Sell
8,988
-47
-0.5% -$4.58K 0.01% 247
2023
Q3 		$949K Buy
9,035
+3,902
+76% +$500K 0.01% 241
2023
Q2 		$660K Sell
5,133
-9
-0.2% -$1.37K ﹤0.01% 265
2023
Q1 		$898K Buy
5,142
+288
+6% +$51.6K ﹤0.01% 247
2022
Q4 		$807K Buy
+4,854
New +$761K 0.01% 249
2022
Q1 		– Sell
-5,588
Closed -$1.83M – 342
2021
Q4 		$1.83M Sell
5,588
-43
-0.8% -$13.5K 0.01% 232
2021
Q3 		$1.7M Sell
5,631
-3,046
-35% -$866K 0.01% 235
2021
Q2 		$2.35M Sell
8,677
-3,319
-28% -$842K 0.01% 224
2021
Q1 		$2.92M Sell
11,996
-1,221
-9% -$336K 0.02% 207
2020
Q4 		$3.79M Buy
13,217
+189
+1% +$52K 0.02% 184
2020
Q3 		$3.32M Sell
13,028
-386
-3% -$91.7K 0.02% 178
2020
Q2 		$2.91M Sell
13,414
-328
-2% -$75.6K 0.02% 184
2020
Q1 		$3.11M Buy
13,742
+217
+2% +$53.5K 0.03% 167
2019
Q4 		$3.37M Buy
13,525
+60
+0.4% +$14.1K 0.02% 189
2019
Q3 		$3.2M Buy
13,465
+21
+0.2% +$4.86K 0.02% 185
2019
Q2 		$3.28M Buy
13,444
+298
+2% +$69.4K 0.02% 179
2019
Q1 		$3.03M Buy
13,146
+313
+2% +$70.7K 0.03% 178
2018
Q4 		$2.67M Sell
12,833
-953
-7% -$186K 0.03% 168
2018
Q3 		$2.56M Buy
13,786
+323
+2% +$65K 0.03% 187
2018
Q2 		$2.84M Buy
13,463
+291
+2% +$50.9K 0.03% 177
2018
Q1 		$1.96M Buy
13,172
+727
+6% +$99.1K 0.02% 214
2017
Q4 		$1.55M Sell
12,445
-100
-0.8% -$14K 0.02% 239
2017
Q3 		$1.87M Buy
12,545
+1,865
+17% +$263K 0.02% 207
2017
Q2 		$1.53M Buy
10,680
+845
+9% +$120K 0.02% 215
2017
Q1 		$1.21M Buy
9,835
+1,050
+12% +$129K 0.01% 230
2016
Q4 		$1.08M Buy
8,785
+1,455
+20% +$182K 0.01% 241
2016
Q3 		$838K Buy
7,330
+2,135
+41% +$243K 0.01% 260
2016
Q2 		$639K Buy
+5,195
New +$560K 0.01% 285

Other funds holding MLAB

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CCA
Conestoga Capital Advisors Wayne, Pennsylvania $5.01B AUM 6.26% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
RIM
Ranger Investment Management Dallas, Texas $1.38B AUM 24.55% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GCM
Geneva Capital Management Milwaukee, Wisconsin $4.71B AUM 6.32% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Bahl & Gaynor's MLAB Position: Q2 2024 in Review

Bahl & Gaynor sold out of Mesa Laboratories (MLAB) in Q2 2024, closing a stake of 8,986 shares — an estimated $986K sold.

Bahl & Gaynor first reported a position in MLAB in Q2 2016 and held it in 29 quarters. The position peaked at $3.79M in Q4 2020. 154 funds tracked by Wall St. Rank hold MLAB as of Q2 2024.

  • Bahl & Gaynor reported no remaining Mesa Laboratories position as of Q2 2024 after selling out during the quarter.
  • Bahl & Gaynor sold 8,986 Mesa Laboratories shares in Q2 2024, an estimated $986K.
  • Bahl & Gaynor first reported a position in Mesa Laboratories in Q2 2016 and held it in 29 quarters.
  • Bahl & Gaynor's Mesa Laboratories position peaked at $3.79M in Q4 2020.
  • 154 funds tracked by Wall St. Rank held Mesa Laboratories as of Q2 2024.

Based on Bahl & Gaynor's 13F filing for Q2 2024, filed 7 Aug 2024.